miR-222在多种癌症中的预后价值：一项系统评价和荟萃分析
Prognostic Value of miR-222 in Various Cancers: a Systematic Review and Meta-Analysis.
作者信息
Wei Tai, Ye Peng, Peng Xin, Wu Li-Ling, Yu Guang-Yan
出版信息
Clin Lab. 2016 Aug 1;62(8):1387-1395. doi: 10.7754/Clin.Lab.2016.160102.
BACKGROUND
MicroRNAs (miRNAs) play important roles in cancer development. MiR-222, which is deregulated in multiple types of cancers, shows potential as a prognostic biomarker; however, the association between miR222 expression and cancer prognosis was controversial in previous studies. Here we analyzed the relationship between miR-222 and the survival of cancer patients.
METHODS
A systematic search of PubMed, Web of Science, Ovid, SciFinder, Cochrane Library, Wan Fang, and the Chinese National Knowledge Infrastructure databases up until June 8, 2015 was performed to clarify the prognostic value of miR-222 in cancers. The hazard ratio (HR) and 95% confidence interval (95% CI) were extracted to evaluate the effect.
RESULTS
Sixteen published articles involving 1,354 patients were included in this meta-analysis. High expression of miR-222 was associated with poor overall survival with a pooled HR of 1.86 (95% CI, 1.57 - 2.14), without significant heterogeneity, and no publication bias was detected.
CONCLUSIONS
Our results showed that high expression of miR-222 is associated with poor overall survival of patients with cancers and could be used as a predictive biomarker for prognosis of various cancers.
背景
微小RNA（miRNA）在癌症发展中起重要作用。miR-222在多种类型癌症中表达失调，显示出作为预后生物标志物的潜力；然而，在先前研究中，miR-222表达与癌症预后之间的关联存在争议。在此，我们分析了miR-222与癌症患者生存之间的关系。
方法
对截至2015年6月8日的PubMed、科学网、Ovid、SciFinder、考克兰图书馆、万方和中国知网数据库进行系统检索，以阐明miR-222在癌症中的预后价值。提取风险比（HR）和95%置信区间（95%CI）以评估效应。
结果
本荟萃分析纳入了16篇已发表文章，涉及1354例患者。miR-222高表达与总体生存率低相关，合并HR为1.86（95%CI，1.57 - 2.14），无显著异质性，且未检测到发表偏倚。
结论
我们的结果表明，miR-222高表达与癌症患者总体生存率低相关，可作为各种癌症预后的预测生物标志物。
Zotero 插件